Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1437-7780
    Keywords: Streptococcus pneumoniae ; Penicillin-resistant ; CBA/J mice ; pneumonia ; β-lactams
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We compared the therapeutic efficacies of penicillin G (PCG), cefotaxime (CTX), and imipenem/cilastatin (IPM/CS) against penicillin-resistantStreptococcus pneumoniae pneumonia in CBA/J mice. In pneumonia induced by strain TUH39 (PCG MIC; 0.063 μg/mL), eight 2.5 mg/kg doses of PCG administered at 1.5 hour intervals beginning 36 hours after infection reduced the number of bacteria in the lungs below the limit of detection. In contrast, a similar regimen failed to lower the number of organisms following infection with strain TUM741 (PCG MIC; 1 μg/mL); however, PCG doses of 8 × 10 and 8 × 40 mg/kg reduced bacterial numbers in a dose-dependent manner. CTX (MIC; 0.5 μg/mL) and IPM/CS (MIC; 0.125 μg/mL) at 6 × 40 mg/kg were more effective than PCG at the same dose against strain TUM741 pneumonia; these antibiotics eradicated bacteria in lungs of 2 out of 5 and 5 out of 5 mice, respectively. In accord with the pulmonary clearance results, survival of mice treated with PCG (6 × 40 and 6 × 160 mg/kg), CTX (6 × 40 mg/kg) and IPM/CS (6 × 40 mg/kg) were 30%, 80%, 40% and 100%, respectively. Pharmacokinetic analysis in lungs revealed that IPM/CS was superior to CTX and PCG in several parameters. These results demonstrate therapeutic responses to CTX, IPM/CS and high-dose PCG in a CBA/J mouse model of penicillin-resistant pneumococcal pneumonia. Results with IPM/CS were particularly favorable, suggesting this antibiotic combination as a potential first-line treatment for penicillin-resistantS. pneumoniae pneumonia.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...